Table 3.

Experimental runs, independent variables, and measured responses of D-optimal design of TNs formulae.

Formulations	X1 Span 60 amount (mg)	X2 Oleic acid amount (mg)	X3 Brij® type	Y1 EE%	Y2 PS (nm)	Y3 PDI	Y4 ZP (mV)
F1	50	50	Brij 93	86.94 ± 4.14	288.10 ± 9.78	0.53 ± 0.08	–22.90 ± 0.36
F2	50	50	Brij 93	86.00 ± 4.20	288.10 ± 10.01	0.53 ± 0.07	–22.00 ± 0.21
F3	50	10	Brij 93	90.48 ± 2.37	430.70 ± 47.38	0.54 ± 0.08	–29.00 ± 0.72
F4	50	10	Brij 58	96.74 ± 1.39	331.80 ± 16.33	0.54 ± 0.07	–20.50 ± 0.17
F5	50	10	Brij 58	96.00 ± 1.56	331.80 ± 20.65	0.53 ± 0.07	–20.00 ± 0.20
F6	50	50	Brij 58	82.65 ± 1.31	376.50 ± 43.33	0.64 ± 0.02	–19.50 ± 0.70
F7	70	10	Brij 93	100.00 ± 1.10	358.60 ± 10.76	0.51 ± 0.004	–30.00 ± 0.80
F8	70	50	Brij 58	90.00 ± 3.58	560.00 ± 8.90	0.59 ± 0.01	–23.90 ± 0.26
F9	70	30	Brij 93	84.73 ± 19.02	507.50 ± 93.02	0.57 ± 0.08	–27.50 ± 1.20
F10	70	20	Brij 58	89.97 ± 1.64	455.30 ± 23.57	0.64 ± 0.05	–20.00 ± 0.80
F11	90	50	Brij 93	98.81 ± 7.75	964.80 ± 48.86	0.76 ± 0.09	–28.20 ± 0.87
F12	90	10	Brij 58	98.90 ± 0.98	235.10 ± 4.12	0.23 ± 0.002	–17.40 ± 0.56
F13	90	10	Brij 93	98.21 ± 1.04	542.70 ± 31.52	0.68 ± 0.01	–24.50 ± 1.50
F14	90	50	Brij 93	96.17 ± 3.07	964.80 ± 48.63	0.75 ± 0.09	–28.20 ± 0.87
F15	90	50	Brij 58	81.00 ± 1.25	825.70 ± 37.05	0.88 ± 0.05	–21.90 ± 0.35

FTN: fenticonazole nitrate; TNs: trans-novasomes; EE%: entrapment efficiency percent; PS: particle size; PDI: polydispersity index; ZP: zeta potential.

All the formulated vesicles included the same amounts of FTN, cholesterol, and Brij^®. Data are displayed as mean ± SD (n = 3).